![]() |
|
|
Vol. 295, Issue 2, 662-669, November 2000
Drug Metabolism and Pharmacokinetics & Bioanalytical Chemistry
(A.Ä.), Experimental Medicine (U.G.E.), and Gastrointestinal
Pharmacology (H.L.), AstraZeneca R&D Mölndal, Mölndal,
Sweden; Department of Pharmacy, Division of Biopharmaceutics and
Pharmacokinetics, Biomedical Center, Uppsala University, Uppsala,
Sweden (M.O.K.); and Drug Metabolism and Pharmacokinetics, AstraZeneca
R&D, Södertälje, Sweden (J.G.)
A turnover model for irreversible inhibition of gastric acid secretion
by omeprazole in gastric fistula dogs was developed using data from
studies with both short- and long-term measurement periods. In the
short-term experiments, after stimulation of acid secretion with
histamine, the dogs were infused i.v. with omeprazole and acid
secretion was measured for 5 h. Dose and infusion times were
varied to produce different concentration-time profiles and schedule
dependence in the inhibitory effect of omeprazole was observed. In the
long-term experiments, dogs were given single intraduodenal
doses, which inhibited the acid secretion for several days. Combining
the short-term and long-term data allowed the observation of a biphasic
recovery of acid secretion that was described by the turnover model.
Second order association rate constants
(kome) for the covalent binding of
omeprazole to H+,K+-ATPase were estimated to 11 and 3.0 l/µmol/h for the i.v. and intraduodenal experiments,
respectively. The apparent turnover rate constant of the enzyme
(kout) was 0.013 h
1 and the
corresponding half-life of inhibition of acid secretory capacity was
54 h. The potency, calculated as kout
over kome, was 4.3 and 1.2 nM for the
intraduodenal and i.v. doses, respectively. Allometric scaling of the
model resulted in trustworthy predictions for observations previously
done in humans. The model predicted a good correlation between maximal
inhibitory effect and exposure (area under the plasma concentration
curve). The time dependence in this relation was also predicted by the model.
This article has been cited by other articles:
![]() |
D. E. Mager, E. Wyska, and W. J. Jusko Diversity of Mechanism-Based Pharmacodynamic Models Drug Metab. Dispos., May 1, 2003; 31(5): 510 - 518. [Abstract] [Full Text] [PDF] |
||||